Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
Total Valuation
Assertio Therapeutics has a market cap or net worth of $58.42M. The enterprise value is $23.41M.
Market Cap$58.42M
Enterprise Value$23.41M
Share Statistics
Assertio Therapeutics has 95,773,090 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding95,773,090
Owned by Insiders2.07%
Owned by Institutions0.05%
Financial Efficiency
Assertio Therapeutics’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -14.43%.
Return on Equity (ROE)-0.18
Return on Assets (ROA)-0.08
Return on Invested Capital (ROIC)-14.43%
Return on Capital Employed (ROCE)-0.14
Revenue Per Employee2.15M
Profits Per Employee-372.09K
Employee Count58
Asset Turnover0.44
Inventory Turnover1.02
Valuation Ratios
The current PE Ratio of Assertio Therapeutics is -3.85. Assertio Therapeutics’s PEG ratio is 0.04.
PE Ratio-3.85
PS Ratio0.00
PB Ratio0.69
Price to Fair Value0.69
Price to FCF3.14
Price to Operating Cash Flow3.14
PEG Ratio0.04
Income Statement
In the last 12 months, Assertio Therapeutics had revenue of 124.96M and earned -21.48M in profits. Earnings per share was -0.23.
Revenue124.96M
Gross Profit85.73M
Operating Income-24.48M
Pretax Income-21.53M
Net Income-21.48M
EBITDA-24.48M
Earnings Per Share (EPS)-0.23
Cash Flow
In the last 12 months, operating cash flow was 26.41M and capital expenditures 0.00, giving a free cash flow of 26.41M billion.
Operating Cash Flow26.41M
Free Cash Flow26.41M
Free Cash Flow per Share0.28
Dividends & Yields
Assertio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.90
52-Week Price Change-41.90%
50-Day Moving Average0.68
200-Day Moving Average0.94
Relative Strength Index (RSI)43.46
Average Volume (3m)392.40K
Important Dates
Assertio Therapeutics upcoming earnings date is May 12, 2025, TBA Not Confirmed.
Last Earnings DateMar 12, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend Date―
Financial Position
Assertio Therapeutics as a current ratio of 1.77, with Debt / Equity ratio of 32.84%
Current Ratio1.77
Quick Ratio1.43
Debt to Market Cap0.47
Net Debt to EBITDA0.44
Interest Coverage Ratio-8.05
Taxes
In the past 12 months, Assertio Therapeutics has paid -52.00K in taxes.
Income Tax-52.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Assertio Therapeutics EV to EBITDA ratio is -2.95, with an EV/FCF ratio of 2.73.
EV to Sales0.58
EV to EBITDA-2.95
EV to Free Cash Flow2.73
EV to Operating Cash Flow2.73
Balance Sheet
Assertio Therapeutics has $100.05M in cash and marketable securities with $40.77M in debt, giving a net cash position of -$60.29M billion.
Cash & Marketable Securities$100.05M
Total Debt$40.77M
Net Cash-$60.29M
Net Cash Per Share-$0.63
Tangible Book Value Per Share$0.43
Margins
Gross margin is 64.02%, with operating margin of -19.59%, and net profit margin of -17.27%.
Gross Margin64.02%
Operating Margin-19.59%
Pretax Margin-17.23%
Net Profit Margin-17.27%
EBITDA Margin-19.59%
EBIT Margin-19.66%
Analyst Forecast
The average price target for Assertio Therapeutics is $2.85, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$2.85
Price Target Upside367.21% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-17.83%
EPS Growth Forecast94.26%